Date: 2012-09-21
Type of information: R&D agreement
Compound: exploration of the genetic data obtained in the Ipsen sponsored EPIGROW study
Company: Ipsen (France) University of Manchester (UK)
Therapeutic area: Hormonal diseases - Endocrine diseases - Rare diseases
Type agreement: R&D
Action mechanism:
Disease: prevalence of IGF-1 deficiency in children with short stature
Details: Ipsen and the University of Manchester have announced that in collaboration with a consortium of investigators from the original study, the University of Manchester will continue the exploration of the genetic data obtained in the Ipsen sponsored EPIGROW study that was aimed at documenting the prevalence of IGF-1 deficiency in children with Short Stature and to identify genetic variations in candidate genes that may be potentially damaging and contribute to the phenotype.
The analysis of the raw data will be performed under the coordination of Peter E Clayton, Professor of Child Health & Paediatric Endocrinology, the University of Manchester, and using deidentified (anonymous) data obtained from 263 prepubertal patients in the EPIGROW study and compared to 263 matched-controls. The results obtained will be used only for research purposes and shared with the scientific community, and in key congresses as well as scientific publications.
Under the terms of the agreement, a steering committee with 6 members representing Ipsen and the University will oversee data obtained by this analysis.
Financial terms:
Latest news:
